Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients

Barnes, David J.; Harris, William H.; Smith, Paul; Millis, Rosemary R.; Rubens, Robert

doi:10.1038/bjc.1996.563

Cited by 220 publications

(138 citation statements)

References 12 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…Consistent and accurate estrogen and progesterone receptors results are important because they are an integral part of therapeutic decision making. [1][2][3] The decision to treat some women with endocrine therapy for up to 10 years is dependent on the results of these tests. The 'Ad hoc' consensus committee has implemented detailed recommendations on estrogen receptor testing by immunohistochemistry.…”

mentioning

confidence: 99%

Delay to formalin fixation effect on breast biomarkers

et al. 2009

View full text Add to dashboard Cite

Delay to formalin fixation may invalidate hormone receptors and HER2 analyses. Invalid results of tumor markers could significantly alter the type of adjuvant therapy a patient receives and potentially impact outcome. The purpose of this study was to determine the effects of progressive delay to formalin fixation on breast cancer biomarkers. Ten palpable invasive breast cancers were resected and underwent immediate gross evaluation. For each case, the procured tumor was divided into eight parts and consecutively fixed after 0, 10, 30 min, 1, 2, 4, and 8 h; one section was kept in saline and stored overnight at 41C. Two tissue microarray blocks were constructed. Estrogen and progesterone receptors and HER2 immunohistochemistry and fluorescence in situ hybridization were carried out. Statistical analyses including non-parametric sign test, exact McNemar's test and Page's L test were used. All 10 cases were invasive ductal carcinomas. Q score X6 was identified in five cases for estrogen receptor and four for progesterone receptor. Mean Q score started to decline at the 2 h mark for estrogen receptor and 1 h mark for progesterone receptor. Lowest score was at 8 h mark for estrogen receptor and overnight for progesterone receptor. HER2 fluorescence in situ hybridization started to be compromised for interpretation at the 1 h mark and became statistically significant at the 2 h mark (Po0.03). To avoid delay to formalin fixation as a factor negatively affecting on breast biomarkers, we recommend not to delay formalin fixation for more than 1 h and not to store specimens overnight.

show abstract

mentioning

confidence: 99%

Delay to formalin fixation effect on breast biomarkers

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In addition to a standardized assay, it is also necessary to demonstrate that IHC yields a similar association with the response of endocrine treatment compared with CYT. For ER this has been demonstrated in some studies for both metastatic (10,14) and primary breast cancer (11,12). So far, less attention has been paid to evaluation of PgR assays in paraffin-embedded material from breast cancer patients treated with tamoxifen (10).…”

mentioning

confidence: 99%

Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies

et al. 2003

View full text Add to dashboard Cite

“…Over the past decade, immunohistochemistry (IHC) has replaced the ligand-binding assay (LBA) for measuring ER and PR. Some studies comparing the predictive values of these two methods found that IHC is an equal or a superior method (Reiner et al, 1986;Stierer et al, 1993;Barnes et al, 1996;Harvey et al, 1999;Mohsin et al, 2004;Regan et al, 2006). However, the definitions of ER and PR positivity by IHC were not consistent among the different studies.…”

Section: Introductionmentioning

confidence: 91%

Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy

Lin

Lien

et al. 2010

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To compare the prognostic prediction between dichotomized and fractionated evaluations of hormone receptor expressions. Methods: Patients with stages I-III breast cancers, who received adjuvant tamoxifen, were enrolled. The expression of estrogen receptor (ER) and progesterone receptor (PR) was evaluated by immunohistochemistry (IHC). A fractionated score (F score), the percentage of positive-staining nuclei (0=none, 1=1%-10%, 2=11%-30%, 3=31%-50%, 4=51%-70%, and 5=71%-100%), was assigned to each case. The dichotomized scoring method defines an F score >1 as positive. The prognostic values of both scores were compared by multiple Cox's proportional hazard models of disease-free survival (DFS) and overall survival (OS). Results: Four hundred and sixteen patients with a median follow-up of 78.0 months were included. F scores for ER and PR correlated directly with DFS and OS. Although both the dichotomized and fractionated ER and PR scores were significantly associated with DFS and OS in univariate analyses, only fractionated ER and PR scores remained as independent prognostic factors of DFS and OS in the final multiple Cox's proportional hazard models. Conclusion: Fractionated IHC hormone receptor expression evaluation enhances the prognostic prediction compared with a dichotomized assessment.

show abstract

Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients

Cited by 220 publications

References 12 publications

Delay to formalin fixation effect on breast biomarkers

Delay to formalin fixation effect on breast biomarkers

Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies

Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy

Contact Info

Product

Resources

About